News und Analysen

In many cases, analysts are guilty of being overly optimistic about the near-term prospects of the stocks they cover. But sometimes they err in a completely opposite way.

Vertex Pharmaceuticals

If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long

You don't need much money to get started investing. And stocks with relatively low share prices have tremendous growth prospects.

Three Fool.com contributors identified no-brainer healthcare stocks

A blast of analyst price target cuts hit Medtronic (NYSE: MDT) stock on Friday, one trading session after the company published its latest set of quarterly earnings. Both the market and several

On the surface, Pfizer (NYSE: PFE) had some good news to report on Thursday. But investors viewed the positive as a negative, in light of its timing. This wasn't helped by an analyst's price-target

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q4 2023 Earnings CallMay 25, 2023, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

Pfizer (NYSE: PFE) has been a losing play for investors over the past 12 months. To wit: The drugmaker's stock has fallen by a whopping 28.8% over this period. Part of that decline has been driven

Shares of the medical device maker Medtronic (NYSE: MDT) were down by 5% on heavy volume as of 10:53 a.m. ET Thursday. The big loss came after the company reported its 2023 fourth-quarter results

Dividend Kings have excellent track records for dividend growth, and are often seen as some of the safest income investments to own. Two dividend growth stocks that may look tempting and that

A good way to diversify your portfolio is to invest in companies in different industries. And if you want to minimize your risk, a good option is to consider investing in industry leaders. Their

Shares of Agilent Technologies (NYSE: A) were sinking 7.9% lower as of 11:34 a.m. ET on Wednesday. The decline came after the life sciences company announced its fiscal 2023 second-quarter results

Medtronic (NYSE: MDT) is on a roll. Its shares have soared close to 15% year to date, easily outperforming the S&P 500.

But is Medtronic a stock to consider buying right now? Here are the bull and

Healthcare stocks make great additions to your portfolio at any time. You generally can count on the biggest players for a certain stability in earnings. That's because, in good times and in bad

The Federal Trade Commission (FTC) has been taking a much more adversarial approach to mergers and acquisitions lately. For instance, it recently said it plans to block the pending deal between

Shares of the Danish pharma giant Novo Nordisk (NYSE: NVO) were down by 3.4% on elevated volume as of 1:14 p.m. ET Tuesday afternoon. The drugmaker's shares are falling in response to the strong

Investors flocked to Pfizer (NYSE: PFE) stock on Monday following some highly encouraging news about one of the company's pipeline drugs. The holy grail of pharmaceutical companies and biotechs is

On May 16, Pfizer (NYSE: PFE) announced that it was going to take out $31 billion in fresh debt to pay for its purchase of Seagen (NASDAQ: SGEN), an oncology drug developer. In total, it'll pay $43

Long-term investors recognize the benefits of a buy-and-hold strategy. The key to earning good returns is to buy good growth stocks and hold them while ignoring short-term headwinds. While 2022 was

Amid the start of the COVID-19 pandemic, big pharma companies like Pfizer (NYSE: PFE) began expedited clinical trials of COVID-19 vaccines and antiviral treatments. And a combination of incredible

We don't have a modern-day Paul Revere riding a horse through the streets shouting that a recession is coming. But we don't need one, as there are plenty of economists, analysts, and even the

Shares of Nutex Health (NASDAQ: NUTX) were up more than 12% Friday afternoon after being up as much as 24% earlier in the day. The company provides technology-driven healthcare management and

Investors who focus on long-term opportunities in the stock market look for well-established companies that are already profitable and have a track record of revenue growth. Two wildly different hea

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months

Inflation rates may finally be cooling down from last year's unnerving levels. However, prices are still rising at a pace above long-term averages, so consumers can't breathe easy just yet -- and

Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If